Collegium Pharmaceutical, Inc. — Operating Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/eeed1ad4-d1d9-4002-b9ac-83e8eae18df5/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $179.6M | 2025-01-01 – 2025-12-31 | evidence 0001628280-26-011992 |
| FY 2024 | $169.9M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-001801 |
| FY 2023 | $167.0M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-001526 |
| FY 2022 | $33.3M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-001900 |
| FY 2021 | $17.6M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-001927 |
| FY 2020 | $56.2M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001814 |
| FY 2019 | $-23.7M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001625 |
| FY 2018 | $-20.7M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001187 |
| FY 2017 | $-75.4M | 2017-01-01 – 2017-12-31 | evidence 0001558370-18-001644 |
| FY 2016 | $-94.1M | 2016-01-01 – 2016-12-31 | evidence 0001558370-17-001629 |
| FY 2015 | $-26.9M | 2015-01-01 – 2015-12-31 | evidence 0001558370-16-004252 |
| FY 2014 | $-17.7M | 2014-01-01 – 2014-12-31 | evidence 0001558370-16-004252 |
| FY 2013 | $-16.0M | 2013-01-01 – 2013-12-31 | evidence 0001558370-16-004252 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Collegium Pharmaceutical, Inc. — all facts · Revenue · Net Income